CSPC Pharma Begins First-in-Human Phase I/II Trial of Trispecific Antibody SYS6088 for Advanced Solid Tumors in China

Bulletin Express11-03 18:40

CSPC Pharmaceutical Group Limited (CSPC Pharma) has officially started a combined Phase I/II clinical trial of SYS6088 injection, a recombinant humanised trispecific antibody designed for patients with advanced solid tumors. The study, registered as SYS6088-001, commenced dosing at the first investigative centre in China following National Medical Products Administration (NMPA) clearance received in October 2026.

SYS6088 simultaneously targets PD-1, VEGFA and CTLA-4, enabling a three-pronged mechanism: re-activation of T-cell cytotoxicity, inhibition of tumor angiogenesis and enhanced T-cell priming. The molecule incorporates Fc engineering to reduce toxicity risks and extend half-life.

The first-in-human trial will assess safety, tolerability, pharmacokinetic characteristics and preliminary antitumor activity in patients with advanced solid tumors. Patient recruitment and screening are currently in progress.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment